PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.67
Both companies show losses. Martin Whitman would check if industry conditions create special situations.
2536.67
P/S above 1.5x AGEN's 25.35. Michael Burry would check for mean reversion risks.
1.46
P/B less than half of AGEN's 155.30. David Dodd would verify if asset quality justifies this discount.
4.13
Positive FCF while AGEN shows negative FCF. John Neff would investigate cash generation advantage.
4.09
Positive operating cash flow while AGEN shows negative OCF. John Neff would investigate operational advantage.
1.46
Fair value ratio less than half of AGEN's 155.30. David Dodd would verify if competitive position justifies this discount.
-6.80%
Both companies show losses. Martin Whitman would check for industry-wide issues.
24.22%
Positive FCF while AGEN shows negative FCF. John Neff would investigate cash generation advantage.